AstraZeneca (AZN)
(Delayed Data from NSDQ)
$79.33 USD
-2.48 (-3.03%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $79.34 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$79.33 USD
-2.48 (-3.03%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $79.34 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Zacks News
What's in the Cards for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) product purchases and introductions in the Rx segment are expected to boost sales.
Ironwood (IRWD) Q2 Earnings & Revenues Miss, Shares Down
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the second quarter. The company will be separated into two entities for better management.
Pharma Stock Roundup: PFE Dominates Headlines, BMY Drug Gets EU Approval
by Zacks Equity Research
Pfizer (PFE) reports strong second-quarter results. European Commission approves Pfizer and Bristol-Myers' (BMY) medicines.
TESARO (TSRO) Misses Earnings and Revenue Estimates in Q2
by Zacks Equity Research
TESARO (TSRO) misses estimates for both earnings and revenues in the second quarter but beats on revenues. Zejula sales increase.
Drug Stocks to Report Q2 Earnings on Jul 31: PFE, INCY, ECYT
by Zacks Equity Research
Let's see how pharma/biotech stocks are poised ahead of their scheduled results on Jul 31.
Pharma Stock Roundup: LLY, AGN Post Solid Q2 Results, ABBV's Elagolix Gets FDA Nod
by Zacks Equity Research
Earnings are in focus this week with Lilly (LLY), Allergan (AGN) and Glaxo (GSK) delivering strong Q2 numbers. AbbVie (ABBV) gains FDA approval for Elagolix.
Merck (MRK) Q2 Earnings & Sales Top on Keytruda Strength
by Zacks Equity Research
Merck (MRK) beat estimates for both earnings and sales in second-quarter 2018. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand trends.
AstraZeneca's (AZN) Q2 Earnings and Sales Beat, Stock Up
by Zacks Equity Research
AstraZeneca (AZN) beats earnings and sales estimates in the second quarter on the back of strong new product sales and maintains previously issued outlook for 2018.
AstraZeneca Sells Atacand's European Rights to Cheplapharm
by Zacks Equity Research
AstraZeneca (AZN) sells Atacand and Atacand Plus' European rights to Cheplapharm Arzneimittel for $210 million.
Ironwood Begins New Phase III Study to Expand Linzess Label
by Zacks Equity Research
Ironwood (IRWD) commences a phase IIIb study in order to add a couple of new symptoms like bloating and discomfort associated with IBS-C to Linzess' label.
Novartis Looks to Exit Antibacterial, Antiviral Program
by Zacks Equity Research
Per media sources, Novartis is looking to exit its antibacterial and antiviral research program, and cut its headcount.
Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit
by Zacks Equity Research
Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.
Biogen's Alzheimer Disease Candidate Succeeds in Phase II
by Zacks Equity Research
Biogen's (BIIB) Alzheimer's disease (AD) candidate demonstrates statistically significant slowdown in disease progression and reduction of amyloid beta accumulation in the brain in a phase II study.
Clovis Gets EU Acceptance for Rubraca Label Expansion Filing
by Zacks Equity Research
Clovis Oncology's (CLVS) regulatory application seeking label expansion of Rubraca as maintenance treatment was accepted for review in Europe.
Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs
by Zacks Equity Research
Novartis (NVS) intends to spin off its Alcon eye care division. The CHMP gives positive opinion recommending marketing approval to several drugs.
AstraZeneca's Two New Cancer Drugs Get Approval in Japan
by Zacks Equity Research
AstraZeneca gets approval in Japan for two new cancer drugs. These include Lynparza for a breast cancer indication and Imfinzi for an early-stage lung cancer indication.
Dow 30 Stock Roundup: Nike, Walgreens Earnings Impress
by Swarup Gupta
The Dow endured a turbulent week, marked by lingering trade tensions.
AstraZeneca/Merck's Lynparza Betters Survival in Phase III
by Zacks Equity Research
AstraZeneca (AZN) and Merck's (MRK) Lynparza significantly delays disease progression in a late-stage study evaluating it for the first-line treatment of advanced ovarian cancer.
Pfizer's Breast Cancer Drug Misses Overall Survival in Study
by Zacks Equity Research
Pfizer (PFE) announces that in the phase III PALOMA-3 study, the combination of Ibrance and Faslodex failed to improve overall survival in women with breast cancer compared with Faslodex and placebo.
Merrimack Crashes as Phase II Pancreatic Cancer Study Fails
by Zacks Equity Research
Merrimack (MACK) plunges, following the announcement of failure of the CARRIE phase II study on pipeline candidate, MM-141, for the treatment of metastatic pancreatic cancer.
Merck (MRK) Presents New Data from Januvia Diabetes Studies
by Zacks Equity Research
Merck (MRK) produces new data from two studies on type II diabetes medicine Januvia (sitagliptin), which supports the drug's clinical profile.
Ironwood Initiates Phase III Studies on Reflux Candidate
by Zacks Equity Research
Ironwood (IRWD) initiates two phase III studies on its gastrointestinal candidate, IW-3718, to evaluate it in persistent gastroesophageal reflux disease.
Merck (MRK) Stock Up So Far This Year on Keytruda Strength
by Zacks Equity Research
Merck's shares are up 8.4% this year driven by strong performance and positive regulatory updates related to its PD-1 inhibitor, Keytruda.
Novo Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study
by Zacks Equity Research
Novo Nordisk (NVO) announces positive headline results of two phase III studies PIONEER oral formulation of Ozempic (semaglutide) as a treatment for adults with type II diabetes.
Valeant Down as FDA Refuses to Approve Duobrii For Psoriasis
by Zacks Equity Research
Valeant (VRX) suffers a setback as the FDA issues a CRL for its plaque psoriasis lotion, Duobrii.